Nano Banana 2 (Gemini 3.1 Flash Image) vs GPT-Rosalind (OpenAI)

Which one should you pick? Here's the full breakdown.

Our Pick

Nano Banana 2 (Gemini 3.1 Flash Image)

A
8.9/10

Google's Gemini 3.1 Flash Image model -- the best-in-class text-in-image renderer, now the default across the Gemini app

GPT-Rosalind (OpenAI)

C
6.8/10

OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)

CategoryNano Banana 2 (Gemini 3.1 Flash Image)GPT-Rosalind (OpenAI)
Ease of Use9.53.0
Output Quality9.59.0
Value8.57.0
Features8.08.0
Overall8.96.8

Pricing Comparison

FeatureNano Banana 2 (Gemini 3.1 Flash Image)GPT-Rosalind (OpenAI)
Free TierYesNo
Starting Price$0Invite only

Which Should You Pick?

Pick Nano Banana 2 (Gemini 3.1 Flash Image) if...

  • Easier to use (9.5 vs 3)
  • Better value for money (8.5/10)
  • Has a free tier

Designers, marketers, and content creators who need readable text in images (social posts, ad creative, book covers, infographics, event flyers) and who are already using or willing to pay for Gemini. If any part of your commercial design work requires typography to look right, Nano Banana 2 is the 2026 leader.

Visit Nano Banana 2 (Gemini 3.1 Flash Image)

Pick GPT-Rosalind (OpenAI) if...

Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.

Visit GPT-Rosalind (OpenAI)

Our Verdict

Nano Banana 2 (Gemini 3.1 Flash Image) is the clear winner here with 8.9/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but Nano Banana 2 (Gemini 3.1 Flash Image) outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.